The CDC's Advisory Committee on Immunization Practices (ACIP) has made several significant vaccine recommendations. The panel unanimously voted to add Merck and Sanofi’s pediatric hexavalent combination vaccine to its preferential recommendation list to help prevent invasive Hib disease in American Indian and Alaska Native infants. Additionally, the ACIP recommended the use of authorized and approved COVID-19 vaccines for the 2024-2025 season, despite concerns over cost-effectiveness. Merck's pneumococcal vaccine also received backing from the CDC panel, positioning it to challenge Pfizer's Prevnar in the market. Meanwhile, Merck stock is slipping.
Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing https://t.co/uYw3ME4WDS
Merck’s pneumococcal vaccine gets CDC panel backing https://t.co/dmp2awrkYr $MRK $PFE by @Lilah_Alvarado
Beware the looming cost factor ... @PharmaPinkSheet #pinksheet #pharma: CDC Advisors Vote For More COVID-19 Vaccines For All Despite Cost-Effectiveness Concerns https://t.co/bqnXbBFGHN
CDC Advisors Vote For More COVID-19 Vaccines For All Despite Cost-Effectiveness Concerns https://t.co/TT50C3eYpS #PinkSheet
NOVAVAX INC - U.S. ACIP RECOMMENDS USE OF AUTHORIZED AND APPROVED 2024-2025 COVID-19 VACCINES
CDC’S ACIP UNANIMOUSLY VOTES TO ADD MERCK AND SANOFI’S PEDIATRIC HEXAVALENT COMBINATION VACCINE TO ITS PREFERENTIAL RECOMMENDATION TO HELP PREVENT INVASIVE HIB DISEASE IN AMERICAN INDIAN AND ALASKA NATIVE INFANTS
Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines. https://t.co/xTE0A5F7uK